AUTHORS
Torsten Steinbrunn, MD, PhD, Christine Riedhammer2, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD3, Kate Milne4, Paula Rodriguez Otero, MD, PhD5, Myo Htut, MD6, Hira Mian, MD7, Alissa Visram, MD, MPH8, Chandramouli Nagarajan, MD, MBBS, FRCP, FRCPath9, Efstathios Kastritis, MD10, Wee Joo Chng11, Laurent Garderet12, Sireesha Asoori, MBBS, MPH13, Carlyn Rose Tan, MD14, Saad Z. Usmani, MD15, Susan Bal, MD16, Jana Mihalyova, MD17, Roman Hajek, MD, PhD18, Joaquin Martinez-Lopez Sr, MD, PhD19, Alberto Blanco, MD20, Juan Du, MD, PhD21, Wanting Qiang, MS22, Kihyun Kim, MD, PhD23, Mrugakshi Dave, MS24, Rahul Banerjee, MD25, Kara I Cicero, MD, MPH26, Prashant Kapoor, MD27, Yi Lin Jr, MD, PhD28, Thomas Martin, MD29, Hermann Einsele, MD, PhD30, Amrita Krishnan, MD, FACP31, Murali Janakiram, MBBS32
AFFILIATIONS
1 University Hospital Würzburg, Würzburg, Germany
2 University Hospital Würzburg, Würzburg, Germany
3 The London Hospital Medical College, London, United Kingdom
4 The London Hospital Medical College, London, United Kingdom
5 Clínica Universidad de Navarra (CCUN), CIMA, CIBERONC, IDISNA, Pamplona, Spain
6 City of Hope National Medical Center, Duarte, California, United States
7 McMaster University, Hamilton, Ontario, Canada
8 Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
9 Singapore General Hospital and National Cancer Centre, Singapore, Singapore
10 National And Kapodistrian University Of Athens, Athens, Greece
11 National University Cancer Institute, Singapore, Singapore
12 Hôspital Universitaire Pitié-Salpêtrière, Paris, France
13 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 University of Alabama at Birmingham, Birmingham, Alabama, United States
17 University Hospital Ostrava, Ostrava, Czech Republic
18 University of Ostrava, Ostrava, Czech Republic
19 Hospital 12 de Octubre, Complutense University, CNIO, Madrid, Spain
20 Hospital 12 de Octubre, Madrid, Spain
21 Shanghai Renji Hospital, Shanghai, China
22 Shanghai Renji Hospital, Shanghai, China
23 Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea, Rep. of South
24 International Myeloma Foundation, Studio City, California, United States
25 Fred Hutchinson Cancer Center, Seattle, Washington, United States
26 Fred Hutchinson Cancer Center, Seattle, Washington, United States
27 Mayo Clinic, Rochester, Minnesota, United States
28 Mayo Clinic, Rochester, Minnesota, United States
29 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
30 University Hospital Würzburg, Würzburg, Germany
31 City of Hope National Medical Center, Duarte, California, United States
32 City of Hope National Medical Center, Duarte, California, United States
ABSTRACT
Background:
TAL, a GPRC5D×CD3 bispecific antibody, has demonstrated significant efficacy in RRMM. While not reported in the initial MonumenTAL-1 trial, cerebellar/vestibular syndromes presenting as ataxia have subsequently emerged as rare but incompletely described neurological adverse events (Janakiram BCJ 2025, Di Palma-Grisi Blood Adv 2026). As TAL is now being evaluated in earlier treatment settings and combination regimens, recognition of this toxicity is increasingly important.
Methods:
This was a retrospective IMWG-sponsored study across 6 international centers of patients (pts) who were treated outside the context of TAL clinical trials. Clinical characteristics, neurologic manifestations (graded using CTCAE v5.0), diagnostic work-up and management, and patient outcomes (using the Kaplan-Meier method) were evaluated for investigator-reported TAL-related ataxia or balance syndrome.
Results:
Of 406 TAL-treated pts, 17 (4.1%) developed ataxia or balance disorders. These 17 pts had received a median of 5 prior lines of therapy (IQR 4;8); 76% were triple-refractory, 53% were penta-refractory, 65% had prior BCMA-directed therapy, and 1 had received a prior GPRC5D-directed CAR-T cell therapy. 14 patients (82%) received single-agent TAL while 3 (18%) received TAL with daratumumab or pomalidomide (18%). 53% harbored high-risk cytogenetics. None of the pts had active CNS involvement at the initiation of TAL treatment. Median follow-up was 6.9 months (range 0.6-60.8 months). Median time to onset of ataxia was 48 days (range 12-637). 12 pts (71%) experienced onset of symptoms within 60 days, including 4 pts (24%) within 30 days of TAL administration. Prior to the development of ataxia symptoms, 12 pts (71%) developed CRS following TAL initiation (64% Gr 1, 27% Gr 2, 9% Gr 3). One patient (5.9%) developed grade 1 ICANS.
Gait ataxia was the predominant manifestation (87%; 13/15), frequently accompanied by dizziness (79%, 11/14), nystagmus (57%, 8/14), dysmetria (43%, 6/14), tremor (29%, 4/14), dysarthria (21%, 3/14), and rarely cognitive impairment (6%, 1/17). Maximum symptom severity was grade 2 in most pts (71%, 12/17), with grade 3 symptoms in 3 pts (18%) and grade 1 symptoms in 2 pts (12%).
Brain MRI was performed in all pts and was unrevealing in most cases; 3 pts demonstrated skull-base lesions, including 1 involving the jugular foramen, not attributable to the cerebellar syndrome. Cerebrospinal fluid analysis was available in 6 pts and demonstrated normal findings in 3 and isolated protein elevation in 3 cases. Potential alternative etiologies were uncommon, with no concurrent infections, no concomitant neurotoxic medications, minimal electrolyte abnormalities, and limited opioid exposure.
Management was primarily supportive, with corticosteroids administered in only 2 patients. At last follow-up, complete neurologic recovery occurred in 5 pts (29%), with a median time from start of ataxia symptoms to complete resolution of 30 days (range 9-184). 8 pts (47%) showed partial improvement of neurological symptoms, and 4 pts (24%) had persistent symptoms without improvement. Patients who had late-onset ataxia >6 months from initiation had no resolution of ataxia. Median time to complete resolution was not reached, and recurrence was observed in 1 patient.
Conclusions:
GPRC5D therapy-related ataxia is an uncommon neurologic toxicity characterized predominantly by dizziness, ataxia, and cerebellar signs, usually of moderate severity. Compared to MonumenTAL-3, our incidence of ataxia with TAL in later lines (predominantly as monotherapy) was lower (4.1% versus 12-15%), while time to onset was earlier (median 48 days vs 292-326 days) and varied widely (range 12-637 days). Therefore, maintaining vigilance throughout the course of TAL is imperative. Conventional neuroimaging and cerebrospinal fluid studies are unrevealing, and recovery is variable. Our study describes the largest cohort of real-world cases of this infrequent toxicity. Recognition is essential to facilitate prompt neurologic evaluation, immediate discontinuation, and optimize supportive management. Future studies should be focused on early recognition and prevention of long-term sequelae.
DISCLOSURES
Torsten Steinbrunn, MD, PhD: travel support from Janssen - Other (including travel support)